Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

NCT01491672 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
134
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals